Brian Goff, Global franchise head for hemophilia, Baxter
Sales force success in the new world of prescribing takes technology. Harris Kaplan and Ann Mayer say substituting e-sampling for rep time could be a game changer for specialty brands. Why this tactic's time is now
For rare diseases and orphan products, the future looks promising, but as Peter Saltonstall finds, significant research, educational and policy challenges remain. A view from one of the patient community's staunchest advocates
With generics firms taking aim at high-flying blockbusters, Big Pharma stalwarts in the asthma and COPD market are pinning their hopes for the future on a flurry of innovative biotech-developed assets. Noah Pines charts the rarefied air of the respiratory space
Here's a countdown of 10 risk-taking ads—five that our industry experts thought truly succeeded, followed by five that might have done better. It's our shout-out to brands that took a risk.
Given the adoption of in-app video and gaming, forward-looking pharma marketers are experimenting with so-called smart DTC on small screens—and the skeptics might not be able to stand in their way much longer
Contact information for companies
Five digital healthcare experts offer elevator insights on the state of digital pharma—the ups, the downs and how to get to the next level
Digital health continued to find a home at the annual consumer electronics shindig in the desert, with fitness, wellness and medical exhibitors up 30%. AstraZeneca's Joe Shields walked the halls to check out what's hot in health tech
At last the FDA has offered some semblance of guidance for digital promotional activities in the medical space. Was it worth the wait? And will it change anything? Peter Pitts picks it apart
If you still crave the comfort of referring to mobile, social media and other digital components as "channels," then at least consider renaming them "human channels." James Chase reports
You have less than eight weeks left to enter the MM&M Awards. No problem. Give yourself the best chance of success by following our checklist of Dos and Don'ts. Good luck!
Hundreds of industry execs assembled in New York to pay tribute to the careers of the 2014 MAHF honorees
The launch front in this category is relatively calm—for now. A movement is brewing to unseat the top diabetes drug, a long-acting insulin, as faster-acting products emerge. Joe Dysart on the intrigue in the metabolic pipeline
As orphan and specialty drugs account for a larger part of total spend, insurers say a barrage of tactics are needed to manage costs. Sarah Morgan on why this is a defining moment
The downward spiral for journals continues. Is anyone surprised? Larry Dobrow on how the fundamental shift to digital continued to affect professional media last year, including the full-year numbers by advertisers and brands
Five areas in which innovative uses of data and analytics promise to improve outcomes along the healthcare continuum. Marc Iskowitz reports
Jorge Bartolome, SVP, US respiratory, GlaxoSmithKline
Tactical ROIs aside, pharma must go beyond the detail to create longer-term value, say Croom Lawrence and Kent Groves, who offer a few tips for new brands
The MM&M Awards 2014 program is officially open for business. This is your chance to put your best work—and people —forward and get the recognition you deserve.
The four newest luminaries honored by the Medical Advertising Hall of Fame built sterling reputations as they advanced their fields. Joshua Slatko looks back on their success and on how each came to be synonymous with their particular niche of healthcare marketing
"New and improved" has entered this space. Alongside the existing compounds that are transforming the lives of patients with orphan ailments, a wave of incrementally better products is coming out. Noah Pines reviews the significant rare-disease market trends
As the Affordable Care Act rolls out, the behaviorists at MicroMass surveyed stakeholders about the impact on industry. Jessica Brueggeman sorts out the diverse views and asks: Can healthcare reform lead pharma to operationalize its patient focus?
Pharma has reduced the burden of disease. It can develop a condition-specific app. But getting people to take their medications as prescribed? That's another matter. Larry Dobrow on why biopharma is backing mobile games for their potential to boost adherence and drive behavior change
With physicians and patients engaging in more cross-platform behavior, marketers must be multi-screen to reach them. Yet only one-third of pharma sites are mobile-optimized. Can we catch up with our customers?
With pharma transforming more rapidly than ever, seven industry vets chart a road map for meeting a changed industry's challenges. James Chase led the discussion.
Despite having the brightest data set of all the oral anticoagulants, the newest one is off to a rocky start. DTC advertising and medical education are under way, but it may take more to revive this launch.
In a year when goliath health portal competitors About.com, Yahoo Health and MSN Health are hemorrhaging visitors, Remedy Health Media is bucking the trend
In a year when high hopes around several launches ended up fizzling, the hottest launch story belongs to biotech, with the debut of Biogen Idec's Tecfidera
Despite a host of challengers, AbbVie has kept Humira atop the hotly competitive anti-TNF and broader autoimmune category
Intouch Solutions ended 2013 with about $70 million in revenue, and 465 employees—seven times the revenue and nearly five times the number of employees it had five years ago.
The skill, nimbleness and unflagging energy with which Amgen tackled some daunting challenges—plus a rich product pipeline and a surge in 2013 sales—made Amgen MM&M's Company of the Year
Pharma marketing is not without its flaws. Last month, seven seasoned industry execs discussed what they might change if they had a clean slate. James Chase kept the peace.
Besides forcing industry to amass a torrent of new data, the Sunshine Act is also expected to wreak havoc on pharma-physician relations. Joe Dysart on the consequences of transparency
These 16 agents, hand-picked from a total field of 164, are poised for approval, and possibly much more. Marc Iskowitz reports
Sanford Bernstein's Dr. Tim Anderson and ISI Group's Dr. Mark Schoenebaum talk about the industry's prospects for 2014
Change is a drag, but there are still several positive signs to be seen in the landscape surrounding the evolving healthcare system, finds Larry Dobrow, who speaks with four sober-minded and esteemed executives
Ezra Ernst, Chief commercial officer, Treato
The industry's bold-faced names and brightest stars got together for an evening of celebration on October 2 at the MM&M Awards.
In MS, a crop of orals has joined the older established therapies, yielding new options—and fierce competition. One thing they can all agree on: there's been a transformation of the treatment landscape in just the last three years. Noah Pines reports
Agencies and clients—are you looking for direction in the way you partner? A little candid advice from the other side may help you stay on course. Larry Dobrow reports
Lifecycle ought to dictate sales approach. So why are mature brands still detailing like it's 2005? Undercover research shows this is a big source of doctor angst. Marc Iskowitz reports
Recognizes and rewards the best integration of different media for a single campaign for maximum measurable effect for clients' companies with $15 billion or more in 2012 worldwide revenue
Recognizes excellence in branded or unbranded TV ads or campaigns promoting a prescription drug, medical product or services, or disease awareness/education
Rewarding excellence in strategic thinking and creative execution of a self-promotion print advertisement/campaign, website, video or other communications channel by a healthcare agency
Recognizes excellence for a print advertisement/campaign, website (company.com), video or other communications channel used to promote a corporate client.
Recognizes excellence in the promotion of drugs, devices, diagnostics and other medical services via sales aids that are distributed directly to HCPs
Recognizes excellence in print ads for the launch of a new prescription drug, medical product or service appearing in any medical journal or periodical.
Rewards the best series of ads for a prescription drug, medical product or service appearing in any medical journals or other periodicals.
Recognizes excellence creative excellence for a single print ad for a prescription drug, medical product or service appearing in any medical journal or periodical
Rewards the best series of ads for a prescription drug, medical product or service appearing in any consumer magazine or newspaper.
Recognizes excellence in smartphone healthcare apps targeting HCPs, including: medical reference libraries for HCPs, promotional apps, patient records resources, med-ed apps and programs that turn smartphones into diagnostic tools or devices
Recognizes excellence from any digital programs targeting healthcare professionals, such as CRM programs, e-detailing, e-CME, online video, 3D animation, interactive live exhibits, video games and interactive sales training for reps
Recognizes excellence from any digital program offering consumers information, tools, education or promotion in the non-medical, health-and-wellness space
Recognizes excellence from any digital program offering consumers information, tools, education or promotion relating to diagnosis, treatment or management of medical conditions and ailments
Recognizes excellence from digital initiatives, targeting either consumers/patients or HCPs, that use social media channels, such as Facebook, Twitter and YouTube
Recognizes excellence for websites promoting education about specific disease states (disease.com) or health issues (issue.com)
Recognizes excellence for websites targeted at healthcare professionals, promoting specific branded products and services (brand.com)
Recognizes excellence for websites targeted at consumers, promoting specific branded products and services (brand.com)
Recognizes excellence for communications efforts promoting awareness and positive perception of healthcare products, services, corporations and organizations to consumers, employees, HCPs, the investor community and other stakeholder groups
Recognizes excellence in direct promotion campaign/materials targeting healthcare professionals
Recognizes excellence in direct promotion campaign materials that are targeting consumers
Recognizes excellence from any print publication and/or web property carrying editorial content directed at healthcare professionals, including medical journals and periodicals
Recognizes excellence from any print publication and/or web property carrying editorial content directed at consumers and patients, including: magazines, newspapers, newspaper sections, custom publications, websites and online versions of print brands
Dagmar Rosa-Bjorkeson, VP/head, US general medicines MS business unit, Novartis
Co-pay initiatives rank among the most hotly debated topics in healthcare marketing today. Pharmas and healthcare providers love them. Payers and PBMs... not so much. Why is that? James Chase takes the moderator's chair
While public health agencies see eye-to-eye with industry on the need to inoculate, vaccination rates among some patient groups remain stubbornly low. Noah Pines on what this means for drug makers, and other areas where industry is rolling up its collective sleeves in an effort to get patients to roll up theirs
Sometimes it's a lateral move. Other times, advancing takes fancy footwork. The main thing, say these six biopharma execs, is to think on your feet. As told to Marc Iskowitz
Getting two unique agency cultures to click is no simple task. Larry Dobrow examines four healthcare-agency unions and finds that marital bliss is possible
Although job-cut announcements have become a part of daily life in the industry, average salaries have risen to an all-time high. Not only that, job satisfaction is up in pharma. However, this doesn't seem to prevent more people than ever looking to move, finds James Chase
Seven industry experts evaluate advances and opportunities in non-personal promotion to physicians, and debate whether brands really need to deploy sales forces. James Chase chairs the discussion
Companies in this space are expanding beyond reproductive health into areas like menopause and osteoporosis. To succeed, they'll need to re-energize their physician and patient base. Noah Pines reports
Generics aren't just ANDAs and patent challenges. Kathy Kovalic on how Marketing and R&D must create a product's value proposition
No one expected the numbers to be pretty. And medical/surgical journals' latest losses weren't. Larry Dobrow analyzes the numbers for the first half of 2013 by advertisers and brands
Marketers say emotion is the spark with which audiences most identify. Marc Iskowitz on five campaigns that connect with consumers
More than 100 industry leaders and thinkers spent hours discussing, reviewing and scoring around 700 entries to the MM&M Awards. Here are the results of their efforts—the 2013 finalists
Seven digital healthcare experts discuss how to turn engaging content across multiple screens into meaningful brand experiences for HCP audiences. James Chase moderates
Noah Pines on the race to market cancer drugs that harness the PD-1 pathway, other standouts in the onolcolgy pipeline, and what's already making waves in the market
While payers' proclivity for print is well-known, many prefer to receive pharma resources digitally, research shows. Joe Dysart on tools that work for this segment.
Can federal data sets and healthcare outcomes grants get data collectors to play nice and scale self-tracking into the larger health system? Larry Dobrow reports
As traditional distinctions lose their relevance, Genzyme's Bill Sibold shows how biotech can retain its competitive edge. Marc Iskowitz reports
Fostering growth by helping clients to embrace "consumer centricity"
Using acquisitions and hires as the building blocks for steady growth
Poised for new opportunities after a successful consolidation
Growing revenues and headcount take small firm into the big leagues
A "new breed of agency" seeks clients who welcome innovation
Flexibility and focus keep agency on the right track for 30 years
Using a broad base of knowledge to go beyond talking global to doing it
Agency with a mission diversifies its base and comes up a winner
Learning to blow its own horn brings this agency a stream of new clients
Finding a unique focus by letting patients speak for themselves
A leader in the rare-disease market is primed for a new burst of growth
A "year of transitions" results in new business and a higher profile
Big consumer shop looks to expand beyond pills, blockbusters
Caught out amid industry changes, a venerable professional shop rebuilds
Making ambitious plans—and then able to deliver on them
Embracing a full-service model and keeping a focus on pharma
Morristown, NJ agency aims to be a one-stop shop for its many clients
"Steady, focused growth" keeps revenues on an upward swing
A "true merger" creates an agency with global reach and deep skills